Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in 1L HPV-Negative R/M HNSCC

Bicara Therapeutics announced that the FDA has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for...